Hepatic Sarcoidosis

Micheal Tadros1, Faripour Forouhar2 and George Y. Wu1

1Department of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT, USA; 2Department of Anatomic Pathology, University of Connecticut Health Center, Farmington, CT, USA

Abstract

Sarcoidosis is a multisystem disease characterized by the presence of non-caseating granulomas in affected organs. Pulmonary involvement is the most common site of disease activity. However, hepatic involvement is also common in sarcoidosis, occurring in up to 70% of patients. Most patients with liver involvement are asymptomatic. Therefore, the majority of cases are discovered incidentally, frequently by the finding of elevated liver enzymes. Pain in the right upper quadrant of the abdomen, fatigue, pruritus, and jaundice may be associated with liver involvement. Portal hypertension and cirrhosis are complications linked to long-standing hepatic sarcoidosis. Liver biopsy is usually required to confirm the diagnosis. It is important to differentiate hepatic sarcoidosis from other autoimmune and granulomatous liver diseases. Not all cases of hepatic sarcoidosis require treatment. For symptomatic patients, the first line treatment includes corticosteroids or ursodeoxycholic acid. Various immunosuppressant agents can be used as second line agents. Rarely, severe cases require liver transplantation.

Epidemiology of hepatic sarcoidosis

In biopsy and autopsy studies of patients with systemic sarcoidosis, liver involvement was found in about 50–80%,17 whereas only 10–30% of patients presented with abnormal liver enzymes during laboratory testing.2,18 The majority of patients with hepatic sarcoidosis are asymptomatic, despite the presence of granulomas on biopsy, abnormal liver enzymes, or radiological evidence of disease.14 It has been reported that the percentage of patients with clinically

Keywords: Sarcoid; Granuloma; Epithelioid.

Abbreviations: ACE, serum angiotensin converting enzyme; AFB, acid-fast bacteria; AMA, anti-mitochondrial antibody; ERCP, endoscopic retrograde cholangiopancreatography; MRCP, magnetic resonance imaging; p-ANCA, peripheral anti-neutrophil cytoplasmic antibody; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis. Received: 21 September 2013; Revised: 9 October 2013; Accepted: 9 October 2013 DOI of original article: 10.14218/JCTH.2013.00016. Correspondence to: George Y. Wu, Department of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT 06030, USA. E-mail: wu@nso.uchc.edu
significant disease is less than 20%. Risk factors associated with hepatic sarcoidosis include African American ethnicity, prior exposure to pegylated interferon, and the presence of splenomegaly. Reports on the differences in prevalence based on gender have been contradictory. In studies containing hundreds of patients, one study reported liver disease to be more common in women, whereas the other showed the opposite.

Spectrum of hepatic sarcoidosis

There is a spectrum of clinical presentations of liver involvement in sarcoidosis. Of the more than 50% of patients who have hepatic granulomas on liver biopsy, only 10–30% have elevated serum liver enzymes. About 20% of patients have palpable hepatomegaly or splenomegaly. Radiological examination (ultrasound or computed tomography) is accurate in the detection of organomegaly, demonstrating this feature in about 40% of cases. However, even in cases of elevated serum liver enzymes or radiological abnormalities, evidence of organ dysfunction is rare.

Some clinical symptoms and signs suggest liver involvement, and may warrant a liver biopsy. Systemic symptoms such as fatigue, fever, and arthralgias are non-specific, but are present in the majority of patients with active liver sarcoidosis. More specific symptoms include jaundice and pruritus, mostly from chronic cholestasis. Right upper quadrant abdominal pain, in theory, results from stretching of the Glisson’s capsule by hepatomegaly as a consequence of the increasing intrahepatic volume occupied by the developing hepatic granulomas. Abdominal pain has been reported to occur in 15% of patients with sarcoidosis, and jaundice in less than 5%.

Long-standing disease has been reported to result in portal hypertension in 3–18% of patients. This may be due initially to compression of portal venules by granulomas, and can result in variceal bleeding. A small proportion (6–8%) of patients can develop portal hypertension because of progression to cirrhosis. Indeed, some patients can develop end-stage liver disease and require liver transplantation.

Investigations

Elevations of alkaline phosphatase and/or gamma glutamyl-transpeptidase have been correlated with cholestasis and liver involvement. Alkaline phosphatase of hepatobiliary origin can be elevated 5–10 times the upper limit of normal. Aminotransferase elevations are usually mild and less frequent compared with elevations in alkaline phosphatase. The severity of liver test abnormalities was shown to be associated with the extent of granulomatous inflammation.

Hyperglobulinaemia may be seen. Measurement of the serum angiotensin converting enzyme (ACE) levels can be useful; they have been reported to be elevated in about 60% of patients with active sarcoidosis. However, the test lacks sensitivity and specificity, with low positive and negative predictive values (84 and 74%, respectively). Normal levels can be seen in chronic forms and in patients who have been on corticosteroids. Therefore, a normal ACE level does not rule out sarcoidosis, but an elevated level may help distinguish sarcoidosis from other granulomatous disease. Elevated ACE levels can also be present in patients with inflammatory bowel disease.

Radiological studies such as ultrasonography, computed tomography (CT), or magnetic resonance imaging (MRI) may show hepatomegaly or multiple hypoattenuated liver nodules. The occurrence of such multiple nodules can be confused with liver metastasis or other granulomatous diseases. The presence of concomitant splenic granulomas may help point towards a diagnosis of sarcoidosis.

Table 1. Postulated mechanisms of liver injury in hepatic sarcoidosis

| Liver injury       | Possible mechanism                                                                 |
|-------------------|-----------------------------------------------------------------------------------|
| Jaundice          | Chronic cholestasis from hepatic fibrosis, bile duct strictures (mimics cholangiocarcinoma) |
|                   | Obstruction of small bile ducts                                                   |
|                   | External compression from a sarcoid mass at the pancreatic head, or porta-hepatis adenopathy |
| Cirrhosis         | Granuloma formation with subsequent hepatic fibrosis, with or without granulomatous phlebitis and thrombosis |
|                   | Secondary biliary cirrhosis                                                       |
| Portal hypertension | Intrahepatic pre-sinusoidal obstruction secondary to granulomas or sinusoidal obstruction from biliary fibrosis or cirrhosis |
|                   | Pre-hepatic obstruction from portal vein thrombosis                               |
|                   | Post-hepatic (hepatic vein thrombosis); Budd-Chiari syndrome                      |
|                   | Portal hypertension can occur without cirrhosis                                  |
| Ascites           | Cirrhosis and portal hypertension                                                |
|                   | Cor pulmonale                                                                     |
|                   | Hypoalbuminemia                                                                   |
|                   | Peritoneal sarcoidosis                                                            |
|                   | Chylous ascites (sarcoid lymphadenopathy)                                         |
Liver biopsy should be considered if the diagnosis is uncertain and treatment is considered. Some authors recommend obtaining a liver biopsy if aminotransferase levels are elevated at least two-fold above the upper limit of normal. Histopathological examination is the definitive diagnostic tool. In sarcoidosis, granulomas are usually abundant and well-formed in the periportal and the portal regions. Typically, the granulomas are non-caseating and epithelioid (Fig. 1). There is scant lymphocytic inflammatory infiltration. Occasionally, fibrinoid necrosis, prominent fibrosis, and multinucleated giant cells can be seen. Staining for acid-fast mycobacteria, and for fungi should be negative. Progression of the disease can result in micronodular cirrhosis.

Differential diagnosis

Hepatic sarcoidosis needs to be differentiated from other (autoimmune) liver diseases, especially primary biliary cirrhosis and primary sclerosing cholangitis. The differential diagnosis of granulomatous liver disease can be separated into four main categories based on the type of granulomas present: epithelioid, foreign body, lipogranulomatous, and lymphohistiocytic. Sarcoid epithelioid granulomas are characterized by macrophages that aggregate to form giant cells surrounded by fibrin rings. Table 4 includes some of these etiologies, and their differentiating characteristics. In the setting of post-transplant granulomas, it is important to remember that the treatment itself can lead to granulomas from drug reaction, and predispose patients to develop opportunistic infections that can cause liver granulomas. In cases of sarcoidosis co-existing with hepatitis C, granulomas may be due to hepatitis C, or may have been induced by prior exposure to interferon therapy for hepatitis C.

Management

When evaluating patients with hepatic sarcoidosis for treatment, consultation with other specialists involved in the patient’s care is recommended to ensure that other organ systems that may be involved with sarcoidosis such as the pulmonary system, central nervous system and/or ocular systems are treated adequately.

Observation without medical management

Observation alone is indicated for patients with asymptomatic liver disease or mild elevations of serum liver enzymes, and normal synthetic liver function without evidence of cholestasis. Hepatomegaly alone noted on physical examination and/or radiographic investigation in the absence of symptoms does not qualify as an indication for treatment. It has been noted that in some asymptomatic patients, abnormal serum liver tests can resolve spontaneously or remain stable for many years.

Medical treatment

For patients who have symptoms of liver involvement, and have biochemical evidence of cholestasis or who are at high risk for developing hepatic complications, pharmacological therapy should be considered. The first line agents that have been studied include corticosteroids and ursodeoxycholic acid.

Steroids

It has been shown that corticosteroids can decrease the number of hepatic granulomas by suppression of the inflammatory response, and reduce liver size which may be helpful for patients with persistent abdominal pain due to hepatomegaly. In addition, steroids are recommended for patients with constitutional symptoms such as fever, fatigue, pruritus, and weight loss. Low-dose prednisone (10–20 mg/daily) may be sufficient for those with mild symptoms, while a higher dose of prednisone (20–40 mg/daily) is warranted for
those with severe symptoms. Prednisone can also be considered for patients with significant adenopathy in the porta hepatis.

Treatment duration should be determined by clinical and laboratory response. Some authors recommend 12 months of therapy before tapering the dose. Relapsing symptoms may require long-term therapy or steroid-sparing agents. Side effects of long-term steroid use (including osteopenia, bone fractures, avascular hip necrosis, hyperglycemia, cataracts, and hypertension) should be considered. No studies have reported on the use of oral budesonide (a systemic steroid eliminated on first pass through the liver) in the treatment of hepatic sarcoidosis.

The benefit of steroids in patients at the extremes of the clinical spectrum (that is, asymptomatic individuals or patients with cirrhosis and portal hypertension) is questionable. Steroids can help in the normalization of these laboratory abnormalities in asymptomatic patients with elevated aminotransferases. However, it is important to consider that serum liver tests can normalize

| Feature                          | PBC                          | Sarcoidosis         | PSC              |
|----------------------------------|------------------------------|---------------------|------------------|
| **Histology**                    | Granulomas - usually few, poorly defined and located in the portal tract along damaged bile ducts, with eosinophils. Florid ductal lesions present in early disease | Granulomas: many, well-formed and usually periportal. Prominent fibrosis and multi-nucleated giant cells. Less prominent biliary injury. | Concentric prominent periductal fibrosis: “onion skin” fibrosis. No granulomas. |
| **Serum Tests**                  | Anti-mitochondrial antibody (AMA) | Serum angiotensin converting enzyme (ACE) | Peripheral anti-neutrophil cytoplasmic antibody (p-ANCA) |
| **Imaging**                      | —                            | —                   | Magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatography (ERCP): generalized beading of the biliary tree |
| **Extra-hepatic disease**        | Rare                         | Pulmonary nodules, hilar lymphadenopathy | Ulcerative colitis |

Fig. 2. A liver biopsy specimen showing: a, a conglomerate of granulomatous reaction (arrow) with significant fibrosis (arrow head); b, significant as well conglomerate of epithelioid granulomas with giant cells (arrow), but without necrosis. Trichrome, × 400.

Fig. 3. A liver biopsy specimen showing a sarcoid granuloma in liver with central fibrinoid necrosis (arrow). H&E, × 400.

Table 3. List of features that distinguish hepatic sarcoid from primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC)
Because there is a lack of long-term studies, it is unclear if steroids prevent liver damage or halt the progression of the disease. In patients with progressive disease (significant fibrosis, chronic cholestasis, and portal hypertension), steroid treatment has not been shown to have beneficial effects. Ursodeoxycholic acid decreases biliary secretion of cholic and chenodeoxycholic acid, and inhibits the intestinal absorption of bile salt. It also helps to modulate the immune response by decreasing HLA class I and class II antigens on the cell membranes of the hepatic and bile duct epithelial cells, respectively. Recent studies have shown a beneficial effect of this agent in the treatment of hepatic sarcoidosis, especially when patients with cholestasis are symptomatic with pruritus. It has the potential effect of delaying the progression of the disease. Given its relative safety compared to steroids, some authors recommend starting with ursodeoxycholic acid before prednisone. In a recent retrospective study of 17 patients comparing placebo vs. prednisone vs. ursodeoxycholic acid, ursodeoxycholic acid was found to be superior in improving aminotransferase levels, pruritus, and fatigue. The usual dose is 13–15 mg/kg orally per day.

**Treatment of advanced liver disease**

Portal hypertension and decompensated cirrhosis should be managed by standard measures. Steroids may not be beneficial, and liver transplantation may be required. Reported rates of graft and patient survival for hepatic sarcoidosis are 78% at 1 year, 66–67% at 3 years, and 60–61% at 5 years. Recurrence of disease in the graft has been reported.

**Prognosis**

The mortality rate of sarcoidosis is about 1–5%. Death usually occurs from severe pulmonary, cardiac, and central nervous system disease rather than hepatic involvement. These survival rates are comparable to other causes of transplantation, except for PBC and PSC.

**Conclusions**

Hepatic sarcoidosis is a granulomatous disease of unknown etiology. Around 70% of patients have epithelioid non-caseating granulomas on liver biopsy; 20–40% of patients have hepatomegaly or elevated liver enzymes. Most of the cases with liver involvement are asymptomatic and do not require treatment. Pain in the right upper quadrant of the abdomen, fatigue, pruritus, and jaundice are the most commonly associated symptoms. For symptomatic patients, prednisone and/or ursodeoxycholic acid may be considered. Those patients who do not respond to steroids and/or ursodeoxycholic acid may require other immunosuppressive agents. Portal hypertension and cirrhosis are possible complications from long-standing hepatic sarcoidosis. Patients may require liver transplantation, but disease recurrence in the graft has been reported, and survival rates tend to be lower than those for patients transplanted for other diseases.
Conflict of interest
None

Author contributions
Writing the medical text (MT), writing the pathology section (FP), organizing and editing the manuscript (GYW).

Acknowledgments
The support of the Herman Lopata Chair in Hepatitis Research (to GYW) is gratefully acknowledged.

References
[1] Culver DA. Sarcoidosis. Immunol Allergy Clin North Am 2012;32:487–511.
[2] Baughman RP, Prison EB. Sarcoidosis. Harrison’s Principles of Internal Medicine 2008:2135–2142.
[3] Permporn P, Chen JH, Tsai TT, Hsieh WC. Sarcoidosis among Chinese in Taiwan. J Formos Med Assoc 1997;96:697–699.
[4] Permporn P, Chou KT, Chu H, Chung YM. Familial sarcoidosis in Taiwan. J Formos Med Assoc 2007;106:499–503.
[5] Rybicki BA, Major M, Popovich Jr. J, Mallarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: A 5-year study in a healthy maintenance organization. Am J Epidemiol 1997;145:234–241.
[6] Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357:2153–2165.2108.
[7] Cosoli M, Fureohu F, Wu CH, Wu GY. Granulomatous liver diseases: A review. J Formos Med Assoc 2012;111:13–13.
[8] Belfer MH, Stevens RW. Sarcoidosis: A primary care review. Am Fam Physician 1998;59:2041–2050.
[9] Takahashi N, Horie T. Heerfordt syndrome. Nihon Rinsho Jpn Clin Med 2002;60:1822–1826.
[10] Zissel G, Prasse A, Muller-Quernheim J. Immunologic response of sarcoidosis. Semin Respir Crit Care Med 2010;31:390–403.
[11] Chesnutt MS, Gifford AH, Prendergast TJ. Pulmonary disorders. Current medical diagnosis & treatment 2010.
[12] Lazarus A. Sarcoidosis: Epidemiology, Pathogenesis, and Genetics. Dig Dis Mon 2009;55:649–660.
[13] Blich M, Edoute Y. Silicosis: to treat or not to treat? Neth J Med 2012;70:349–356.
[14] Valla D, Pasqueur–Miranda H, Degott C, Lebrec D, Rueff B, Benhamou JP. Sarcoidosis complicated by cirrhosis and hepatoportal syndrome. Can Respir J 2008;15:124–126.
[15] MacArthur KL, Forouhar F, Wu GY. Intra-abdominal complications of sarcoidosis. J Formos Med Assoc 2010;109:553–557.
[16] Abramson SH, Adab N, WM, Xu R. Budd-Chiari syndrome in sarcoidosis involving liver. Liver Int 2008;28:580–581.
[17] Vatta R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis. J Clin Gastroenterol 2004;39:177–180.
[18] Vatta R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis. J Clin Gastroenterol 2004;39:177–180.
[19] Vatta R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis. J Clin Gastroenterol 2004;39:177–180.
[20] Vatta R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis. J Clin Gastroenterol 2004;39:177–180.
[21] Vatta R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis. J Clin Gastroenterol 2004;39:177–180.
[22] Vatta R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis. J Clin Gastroenterol 2004;39:177–180.
[23] Vatta R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis. J Clin Gastroenterol 2004;39:177–180.
[24] Vatta R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis. J Clin Gastroenterol 2004;39:177–180.
[25] Vatta R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis. J Clin Gastroenterol 2004;39:177–180.
[26] Vatta R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis. J Clin Gastroenterol 2004;39:177–180.
[27] Vatta R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis. J Clin Gastroenterol 2004;39:177–180.
[28] Vatta R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis. J Clin Gastroenterol 2004;39:177–180.
[29] Vatta R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis. J Clin Gastroenterol 2004;39:177–180.
[30] Vatta R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis. J Clin Gastroenterol 2004;39:177–180.
[57] Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127:1064–1071.
[58] Fidler HM, Hadziyannis SJ, Dhillon AP, Sherlock S, Burroughs AK. Recurrent hepatic sarcoidosis following liver transplantation. Transplant Proc 1997;29:2509–2510.
[59] Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Eur Respir J 1999;14:735–737.
[60] Iwai K, Tachibana T, Hosoda Y, Matsui Y. Sarcoidosis autopsies in Japan. Frequency and trend in the last 28 years. Sarcoidosis 1988;5:60–65.
[61] Casavilla FA, Gordon R, Wright HI, Gavaler JS, Starzl TE, Van Thiel DH. Clinical course after liver transplantation in patients with sarcoidosis. Ann Intern Med 1993;118:865–866.
[62] Barbers RG. Role of transplantation (lung, liver, and heart) in sarcoidosis. Clin Chest Med 1997;18:865–874.